CD73 induces gemcitabine resistance in pancreatic ductal adenocarcinoma: A promising target with non-canonical mechanisms. (28th October 2021)
- Record Type:
- Journal Article
- Title:
- CD73 induces gemcitabine resistance in pancreatic ductal adenocarcinoma: A promising target with non-canonical mechanisms. (28th October 2021)
- Main Title:
- CD73 induces gemcitabine resistance in pancreatic ductal adenocarcinoma: A promising target with non-canonical mechanisms
- Authors:
- Yu, Xiaozhou
Liu, Weishuai
Wang, Ziyang
Wang, Hongwei
Liu, Jing
Huang, Chongbiao
Zhao, Tiansuo
Wang, Xiuchao
Gao, Song
Ma, Ying
Wu, Liangliang
Li, Xiaofeng
Yang, Shengyu
Hao, Jihui - Abstract:
- Abstract: CD73, a cell surface-localized ecto-5′-nucleotidase, is the major enzymatic source of extracellular adenosine. Canonically, it plays multiple roles in cancer-related processes via its metabolite. As a druggable target, clinical trials targeting CD73 in various malignant diseases are currently ongoing. Here, we report the ecto-5′-nucleotidase-independent functions of CD73 in pancreatic ductal adenocarcinoma (PDAC). Our findings support that the elevated expression of CD73 in PDAC cells promotes gemcitabine (GEM ) resistance by activating AKT. We discovered that a large amount of intracellular CD73 are localized in the endoplasmic reticulum membrane. Intracellular CD73 physically interacts with major vault protein to activate the SRC–AKT circuit. Troglitazone (TGZ) is a peroxisome proliferator-activated receptor gamma agonist that could inhibit the expression of CD73. The administration of TGZ markedly enhances sensitivity to GEM via downregulating CD73 in PDAC. Our findings support that CD73 could be targeted to overcome chemoresistance in PDAC. Highlights: Elevated expression of CD73 in PDAC induces GEM resistance. CD73 functions via a nucleotidase-independent mechanism in PDAC cells. Abundant intracellular CD73 localized in the ER functions via PPIs. Intracellular CD73 physically interacts with MVP to activate the Src–Akt circuit. TGZ enhances sensitivity to GEM via downregulating CD73 in PDAC.
- Is Part Of:
- Cancer letters. Volume 519(2021)
- Journal:
- Cancer letters
- Issue:
- Volume 519(2021)
- Issue Display:
- Volume 519, Issue 2021 (2021)
- Year:
- 2021
- Volume:
- 519
- Issue:
- 2021
- Issue Sort Value:
- 2021-0519-2021-0000
- Page Start:
- 289
- Page End:
- 303
- Publication Date:
- 2021-10-28
- Subjects:
- Pancreatic ductal adenocarcinoma -- CD73 -- Gemcitabine -- Major vault protein -- SRC -- Troglitazone
Cancer -- Periodicals
Neoplasms -- Periodicals
Cancer -- Périodiques
Electronic journals
616.994 - Journal URLs:
- http://www.sciencedirect.com/science/journal/03043835/ ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.canlet.2021.07.024 ↗
- Languages:
- English
- ISSNs:
- 0304-3835
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3046.485000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 18489.xml